Overt thyroid toxicity during treatment significantly prolonged OS and PFS in patients with metastatic melanoma, NSCLC, and renal cell carcinoma (RCC) receiving anti–PD-1. This evidence concerns the gene PDCD1 and metastatic melanoma.